Literature DB >> 8983088

Corticosteroid receptor mediated effects on mood in humans.

W Plihal1, R Krug, R Pietrowsky, H L Fehm, J Born.   

Abstract

The present double-blind cross-over study aimed to discriminate effects of dexamethasone (DEX) and cortisol (CORT) on mood in ten healthy men. DEX is assumed to predominantly activate glucocorticoid receptors (GR) whereas CORT binds central nervous mineralocorticoid receptors (MR) as well as GR. Mood was assessed by an extensive adjective checklist (Eigenschaftswoerterliste) every morning during two 7-day experimental periods. During one of these periods, subjects were subchronically treated with placebo, during the other they received DEX (4 mg/day). On days 5 and 7 of these periods, (in a balanced manner) either placebo or CORT (10 mg/h) was infused during the night (9 h) before mood assessment. DEX, acutely, enhanced activation, concentration, and arousal (p < .05). During prolonged DEX administration, the energizing effect of the glucocorticoid decreased, but emotional arousability and negative feelings (anger, sadness) were significantly enhanced. CORT administered during prolonged DEX treatment, counteracted these negative feelings, and enhanced scores on a dimension of "high spirits". Sole administration of CORT also enhanced "high spirits" (p < .05) and, like DEX, activation and concentration (p < .05). Results suggest GR to mediate an energizing effect and, with prolonged activation, a dysphoric influence on mood. Predominant activation of MR appears to mediate changes towards euphoric mood.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983088     DOI: 10.1016/s0306-4530(96)00011-x

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  6 in total

1.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

2.  A randomised placebo-controlled trial of oral hydrocortisone for treating tobacco withdrawal symptoms.

Authors:  Michael Ussher; Paul Aveyard; Fiona Reid; Robert West; Phil Evans; Angela Clow; Frank Hucklebridge; Julie Fuller; Judith Ibison; Andrew Steptoe
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

3.  Mineralocorticoid receptor and glucocorticoid receptor work alone and together in cell-type-specific manner: Implications for resilience prediction and targeted therapy.

Authors:  Nikolaos P Daskalakis; Onno C Meijer; E Ron de Kloet
Journal:  Neurobiol Stress       Date:  2022-04-22

4.  Effects of stress on responses to methamphetamine in humans.

Authors:  Anna Söderpalm; Lilia Nikolayev; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

5.  Snoozing: an examination of a common method of waking.

Authors:  Stephen M Mattingly; Gonzalo Martinez; Jessica Young; Meghan K Cain; Aaron Striegel
Journal:  Sleep       Date:  2022-10-10       Impact factor: 6.313

6.  Relative hypo- and hypercortisolism are both associated with depression and lower quality of life in bipolar disorder: a cross-sectional study.

Authors:  Martin Maripuu; Mikael Wikgren; Pontus Karling; Rolf Adolfsson; Karl-Fredrik Norrback
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.